Long-acting rilpivirine (RPV LA) has been proposed for use as pre-exposure prophylaxis (PrEP) and the prevalence of transmitted RPV-resistant viruses can be relatively high in some populations. We studied how effectively RPV LA could inhibit vaginal transmission of WT HIV-1 as well as two RPV-resistant mutants.
Plasma and female genital tract (FGT) RPV pharmacokinetics were determined after a single dose of RPV LA in female humanized BLT mice. Vaginal virus challenges of WT, Y181C, and Y181V HIV-1 were performed in untreated animals and after RPV PrEP when plasma and FGT concentrations were either at biologically relevant (low) or 7- to 9-fold higher (high) concentrations (n=6-10 per group). Quantitative RT-PCR was used measure plasma viremia in the mice until 10 weeks post-challenge. Single-genome sequencing of the reverse transcriptase coding region was performed on plasma HIV-1 RNA in mice infected during PrEP treatment.
Y181C HIV-1 conferred 2-fold resistance and Y181V HIV-1 conferred 30-fold resistance to RPV in vitro. High RPV concentrations delayed dissemination of a highly infectious WT HIV-1 clone (p>0.05) and completely inhibited Y181C HIV-1 (p=0.02). However, high RPV concentrations did not inhibit Y181V HIV-1. Biologically relevant RPV concentrations did not significantly inhibit vaginal transmission of WT or Y181C HIV-1. New mutations associated with low-level RPV were detected in 25% of mice infected during RPV LA PrEP usually at frequencies of <5% of HIV-1 RNA genomes. E138K and mutations that do not confer RPV resistance (M184I and V179I) were also observed in some mice. E138K and M184I previously were shown to develop via APOBEC3-mediated hypermutation.
Biological concentrations of RPV in the genital tract and plasma were not sufficient to prevent vaginal transmission of a highly infectious HIV-1 molecular clone. While 8-fold higher RPV concentrations inhibited low RPV-resistant Y181C HIV-1, they were not sufficient to inhibit Y181V HIV-1, which has 30-fold resistance to RPV. Our data suggest that both level of resistance and infectivity affect the ability of HIV-1 to be transmitted during PrEP. HIV-1 did not develop high level or high frequency RPV resistance most mice infected during RPV LA PrEP. The impact of low frequency RPV-resistant viruses on virologic outcome during antiretroviral treatment remains to be determined.